Clinical trials: Hepatic
Liver Diseases
A Study of Dasatinib to See How Liver Impaired and Healthy Subjects Process and React to the Study Drug
The primary purpose of this study is to evaluate how a person with liver impairment processes and reacts to the study drug. Information about any side effects that may occur will also be collected.
- Trial name
- NCT00382668
- Testing
- Dasatinib
- Where
- 4 sites in United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
Hepatic Impairment, Healthy Volunteers
A Research Study Looking at How a Single Dose of the Study Medicine NNC0194-0499 Behaves in Participants With Reduced Liver Function Compared to Participants With Normal Liver Function
The study medicine NNC0194-0499 is under development for non-alcoholic fatty liver disease (NAFLD) including non-alcoholic steatohepatitis (NASH).
- Trial name
- NCT05917938
- Testing
- NNC0194-0499
- Where
- 5 sites in Germany, Poland and 1 more
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
Hepatic Insufficiency
Pharmacokinetics and Pharmacodynamics of BI 1356 in Subjects With Different Degrees of Liver Impairment as Compared to Healthy Subjects
To investigate the influence of mild, moderate, and severe liver impairment on the pharmacokinetics and pharmacodynamics of linagliptin in comparison with a control group with normal hepatic function after single or multiple oral…
- Trial name
- NCT02183376
- Testing
- BI 1356
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Nonalcoholic Fatty Liver Disease
Effects of Exenatide (Byetta®) on Liver Function in Patients With Nonalcoholic Steatohepatitis (NASH)
The primary objective is to test the hypothesis that 24 weeks of treatment with exenatide will improve the histological acitvity of NASH (steatosis,necroinflammation, ballooning), summarized in the recently introduced NASH-score…
- Trial name
- NCT01208649
- Testing
- Exenatide
- Where
- Germany
- Volunteers
- 13 people, healthy volunteers welcome
- Sponsor
- Ruhr University of Bochum
Depressive Disorder, Major
A Study of LY2216684 in Participants With Impaired Hepatic Function
The purpose of this study is to evaluate the effect of liver function on how much of the study drug (LY2216684) gets into the blood stream and how long it takes the body to get rid of it.
- Trial name
- NCT01241435
- Testing
- LY2216684
- Where
- 3 sites in United States
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Metabolic Syndrome
Effects of an Amino-acid Supplement on Hepatic Lipid Metabolism
10 healthy male volunteers will be studied after a 6 day weight maintenance, balanced diet a 6 days weight maintenance, balanced diet supplemented with 3 grams fructose/kg body weight/day a 6 days weight maintenance, balanced…
- Trial name
- AMINOFRUCT (NCT01119989)
- Testing
- amino-acid + fructose
- Where
- Switzerland
- Volunteers
- 9 people, healthy volunteers welcome
- Sponsor
- University of Lausanne
Implantable Cardioverter-Defibrillator, Health Information Exchange
Electronic Patient Notification of Remote ICD Data: Impact of Patient Engagement on Outcomes in the Merlin.Net™
Remote monitoring of implantable cardioverter-defibrillators (ICDs) for patients has led to efficient, safe, and satisfying analysis of their device and cardiac status; resulting in an overall improvement in the quality of care…
- Conditions
- Implantable Cardioverter-Defibrillator, Health Information Exchange, Electronic Health Records, Patient Participation
- Trial name
- ePHR-ICD-SJM (NCT02989090)
- Testing
- Receive Detailed ICD Information-electronic, Receive Detailed ICD Information-paper
- Where
- United States
- Volunteers
- 191 people, healthy volunteers welcome
- Sponsor
- Parkview Hospital, Indiana
Pediatric Liver Transplanted Recipients, Healthy Donors
Living Donor Liver Transplantation in Children
Evaluate the outcome of pediatric living donor liver transplantation (LDLT) regarding portal vein reconstruction, ABO-compatibility and impact of maternal donation on graft acceptance.
- Trial name
- NCT02124382
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Esophageal Varices in Cirrhosis of the Liver
Radiomics-based Surrogate of Endoscopy (rEndosc) (CHESS1703)
Esophageal varices (EVs) resulting from portal hypertension are a prevalent complication of cirrhosis with a high mortality when variceal hemorrhage (VH) occurs.
- Trial name
- rEndosc (NCT03373123)
- Testing
- Endoscopy, CTA
- Where
- 9 sites in China
- Volunteers
- healthy volunteers welcome
- Sponsor
- Nanfang Hospital, Southern Medical University
Liver Transplant; Complications, Cirrhosis
Technology Enabled Strategies to Promote Treatment Adherence in Liver Transplant
Liver transplantation is increasingly performed for older adults with multiple comorbidities. Medication adherence is key to maintaining proper function of the transplanted liver and optimize health; however, adhering to…
- Conditions
- Liver Transplant; Complications, Cirrhosis, End Stage Liver DIsease, Medication Adherence
- Trial name
- TEST (NCT05260268)
- Testing
- TEST Intervention
- Where
- 3 sites in United States
- Volunteers
- 361 people, healthy volunteers welcome
- Sponsor
- University of Pennsylvania
Liver Cirrhosis
Hepatic Sugar Metabolism Measured by PET/CT in Patients and Healthy Subjects
The investigators wish to determine the lumped constant (LC), which is a correction factor necessary for converting measurements of hepatic FDG metabolism (measured by PET) to those of regular glucose in patients with cirrhosis…
- Trial name
- NCT01369979
- Testing
- Liver vein catheter
- Where
- Denmark
- Volunteers
- 13 people, healthy volunteers welcome
- Sponsor
- University of Aarhus
Healthy, Hepatic Insufficiency
A Study of the Pharmacokinetics and Safety of LY3537031 in Participants With Normal Liver Function and With Mild, Moderate, or Severe Liver Impairment
The purpose of this study is to measure how much LY3537031 gets into the bloodstream and how long it takes the body to eliminate it in participants with mild, moderate and severe impaired liver function and in healthy…
- Trial name
- NCT07165002
- Testing
- LY3537031
- Where
- 3 sites in Hungary, New Zealand and 1 more
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Hepatic Impairment
Pharmacokinetics of BAF312 in Patients With Hepatic Impairment
This study will investigate the pharmacokinetics of BAF312 in patients with mild, moderate and severe hepatic impairment compared to healthy control subjects.
- Trial name
- NCT01565902
- Testing
- BAF312
- Where
- 3 sites in Hungary, Russia
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Novartis Pharmaceuticals
Liver Disease
A Study to Assess the Effect of Severe Hepatic Impairment on the Pharmacokinetics of Intravenous Conivaptan
The purpose of this study is to assess the pharmacokinetics and safety of a 48-hour continuous infusion of conivaptan in subjects with severe liver impairment compared to subjects with normal liver function.
- Trial name
- NCT01370148
- Testing
- conivaptan hydrochloride
- Where
- 3 sites in United States
- Volunteers
- 17 people, healthy volunteers welcome
- Sponsor
- Cumberland Pharmaceuticals
Diabetes Mellitus
Investigation of Pharmacokinetics and Safety of HRS-7535 in Subjects With Hepatic Impairment and Normal Hepatic Function
The study is being conducted to compare the pharmacokinetics and safety of HRS-7535 in subjects with mild to moderate hepatic impairment and normal hepatic function.
- Trial name
- NCT06961643
- Testing
- HRS-7535 Tables
- Where
- China
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Shandong Suncadia Medicine Co., Ltd.
Hepatic Impairment
Study of Nalbuphine ER in Participants With Hepatic Impairment
This research study will evaluate the effect of hepatic impairment on the pharmacokinetics (the breakdown of the drug in the body) of parallel-group, multiple oral doses nalbuphine extended release (NAL ER), tablets in people…
- Trial name
- NCT04020016
- Testing
- Nalbuphine ER
- Where
- 3 sites in United States
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Trevi Therapeutics
Hepatocellular Carcinoma
A Novel Immunotherapy PD-1 Antiboty to Suppress Recurrence of HCC Combined With PVTT After Hepatic Resection
Hepatic resection is the most effective curative treatment for resectable HCC, whereas frequent recurrence usually impaired the efficacy of hepatic resection and contributed poor survivals.
- Trial name
- NCT03914352
- Testing
- PD-1 antibody, TACE
- Where
- China
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Cancer Hospital of Guangxi Medical University
Hepatic Impairment
MEK162 in Healthy Subjects With Normal Hepatic Function and Subjects With Impaired Hepatic Function
This study is a phase I, multi-center, open-label, single oral dose, parallel group study to assess the PK and safety of MEK162 in subjects with impaired hepatic function and healthy subjects with normal hepatic function.
- Trial name
- MEK162 (NCT02050815)
- Testing
- MEK162
- Where
- 5 sites in United States
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- Array Biopharma, now a wholly owned subsidiary of Pfizer
Microbial Colonization
Correlation Between Intestinal Microbiota, Inflamatory Biomarkers, Intestinal Morphology, Hepatic Fibrosis Degree and Vascular Reactivity.
Metabolic, inflammatory status, intestinal permeability biomarkers, and gut microbiota composition were investigated in individuals with varying levels of adiposity and glucose tolerance.
- Trial name
- NCT03178006
- Volunteers
- 46 people, healthy volunteers welcome
- Sponsor
- Rio de Janeiro State University
Hepatic Impairment
Open-Label Study to Evaluate the Safety, Tolerability, and PK of Aramchol in Subjects With Hepatic Impairment
Phase 1, multicenter, open-label, 2-part, single- and multiple-dose study designed to assess the effect of hepatic insufficiency on the PK of aramchol
- Trial name
- NCT04480827
- Testing
- Aramchol free acid tablet 600mg, single dose, Aramchol free acid tablet 300mg, bid
- Where
- 3 sites in United States
- Volunteers
- 57 people, healthy volunteers welcome
- Sponsor
- Galmed Research and Development, Ltd.